Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Mako Surgical Corp.’s (NSDQ:MAKO) commercial launch of the RIO surgical robotic arm for hip replacement surgery won some love from analysts and investors on Wall Street today.
A federal judge in Massachusetts tossed a shareholders’ lawsuit accusing Boston Scientific Corp. (NYSE:BSX) of fraudulently concealing problems within its cardiac rhythm management division that prompted it to fire several members of its CRM sales force.
Medtronic scored a big win yesterday in its patent war with NuVasive Inc., after a California jury awards it $101.2 million in damages over spinal implant technology; NuVasive, which won a $660,000 award for Medtronic’s infringement of one of its patents, vows to fight the decision.
Advanced Cell Technology Inc. (OTC:ACTC) is set to begin Europe’s first study involving human embryonic stem cells, as it begins a trial to consider an experimental treatment for a form of juvenile blindness.
Personal injury lawsuits over its controversial Infuse bone-growth protein are beginning to pile up for Medtronic Inc. (NYSE:MDT) and a Minnesota judge ordered the medical device colossus to turn over safety data.
C.R. Bard (NYSE:BCR) announced a $68.5 million deal in place to acquire Clearstream Technologies, an Ireland-based developer of catheters used in angioplasty procedures.
The terms of Michael Mahoney’s move from Johnson and Johnson (NYSE:JNJ) to well-paid president – and eventual CEO – at its Natick, Mass.-based rival, Boston Scientific (NYSE:BSX), were driven by a strict non-competition agreement between J&J and Mahoney.